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Background: The accumulation of activated microglia is a hallmark of various neurodegenerative diseases. Microglia
may have both protective and toxic effects on neurons through the production of various soluble factors, such as
chemokines. Indeed, various chemokines mediate the rapid and accurate migration of microglia to lesions. In the zebra
fish, another well-known cellular migrating factor is fibroblast growth factor-2 (FGF-2). Although FGF-2 does exist
in the mammalian central nervous system (CNS), it is unclear whether FGF-2 influences microglial function.
Methods: The extent of FGF-2 release was determined by ELISA, and the expression of its receptors was examined
by immunocytochemistry. The effect of several drug treatments on a neuron and microglia co-culture system was
estimated by immunocytochemistry, and the neuronal survival rate was quantified. Microglial phagocytosis was
evaluated by immunocytochemistry and quantification, and microglial migration was estimated by fluorescence-activated
cell sorting (FACS). Molecular biological analyses, such as Western blotting and promoter assay, were performed to
clarify the FGF-2 downstream signaling pathway in microglia.
Results: Fibroblast growth factor-2 is secreted by neurons when damaged by glutamate or oligomeric amyloid
β 1-42. FGF-2 enhances microglial migration and phagocytosis of neuronal debris, and is neuroprotective against
glutamate toxicity through FGFR3-extracellular signal-regulated kinase (ERK) signaling pathway, which is directly
controlled by Wnt signaling in microglia.
Conclusions: FGF-2 secreted from degenerating neurons may act as a ‘help-me’ signal toward microglia by inducing
migration and phagocytosis of unwanted debris.
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Neuron and glial cells are in close association with each
other and maintain physiological function in the central
nervous system (CNS). When their finely controlled inter-
actions are impaired by inflammation and stress condi-
tions, neuronal networks are damaged, which results in
the pathogenesis of several neurodegenerative diseases [1-3].
It has been proposed that apoptotic cells or degenerating
neurons release various signals to surrounding glial cells.* Correspondence: tmizuno@riem.nagoya-u.ac.jp
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unless otherwise stated.These signals have been recently classified as ‘find-me’,
‘help-me’, and ‘eat-me’ signals [4-8].
Microglia are resident immune cells in the CNS and
express many versatile receptors [9]. Therefore, they are
considered the main recipient of various signals from
degenerating neurons. Moreover, microglia exhibit early
and rapid responses to various stimuli; for instance, acti-
vated microglia accumulate at pathological lesions [10].
The rapid and accurate migration of microglia to lesions
is predominantly mediated by various chemokines [11].
In addition to chemokines, fibroblast growth factor
(FGF)-2 regulates cellular migration in developing brain
and in zebra fish [12-15]; however, FGF-2 has not been
directly implicated in microglial migration.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has a variety of functions, including inducing the prolifera-
tion and differentiation of various cell types, such as fibro-
blasts. Twenty-two types of FGF have been identified in
human beings, as well as in mice. FGF-2 (basic FGF), one
of the most common FGFs, has attracted attention for its
widespread activity, such as cell proliferation, carcinoma
cell invasion, neoangiogenesis, osteogenesis, and differen-
tiation of developmentally staged constituent cells of the
CNS [16-19]. FGF-2 is expressed in various tissues at low
levels, but its concentration is much higher in the brain.
Five types of FGF receptor (FGFR: FGFR1 to 5) have been
identified to date [20], but their detailed expression levels
in individual cells and mode of action in the CNS have
not been elucidated. However, the expression levels of
FGF-2 and FGFR have been shown to be up-regulated in
CNS injury [21]. Furthermore, several reports show that
astrocytes, but not neuronal cells, are the dominant FGF-
2-producing cells in the CNS [16-19].
FGF-2 plays important roles in various cells in the CNS.
Indeed, morphological change in glial cells and reactivity
in vivo [22] have been demonstrated with FGF-2 injection
into the cerebrospinal fluid. The best known FGF recep-
tor–related signaling is MAPK, which is the common
downstream signaling pathway of all FGFR subtypes. FGF-
2 is known to induce Wnt/β-catenin signaling in human
endothelial cells and developing the zebra fish brain
[12,23,24], but it is unclear whether FGF-2 also regulates
Wnt/β-catenin signaling in microglia under neurodegen-
erative conditions.
In this study, we found that FGF-2 was secreted by glu-
tamate or oligomeric amyloid β (oAβ) from damaged neu-
rons, but not from astrocytes or microglia. Degenerating
neurons produce signaling molecules that attract sur-
rounding cells including microglia. Among these signaling
molecules, we revealed FGF-2 as a predominant coordin-
ator of microglial migration. FGF-2 induced microglial
neuroprotection, migration and phagocytosis of neuronal
debris via FGFR3. Furthermore, downstream signaling
of FGF-2, especially through the FGFR3-extracellular
signal-regulated kinase (ERK) signaling pathway, led to
microglia-mediated neuronal survival. Wnt signaling
directly induced this ERK phosphorylation and microglial
migration, which were each enhanced by FGF-2 stimula-
tion. Together, our results demonstrate that FGF-2 could
be a key signaling molecule for crosstalk between degener-
ating neurons and microglia, and that the FGFR3/ERK/




L-glutamate and goat immunoglobulin G (IgG), mouse
IgG, and rat IgG were purchased from Sigma (St. Louis,MO, USA). Mouse recombinant FGF-2, mouse recombin-
ant fractalkine (FKN; the chemokine domain), CCL21,
and the FGFR (FGFR2-5) neutralizing antibodies were ob-
tained from R & D Systems (Minneapolis, MN, USA). The
MAPK inhibitors (U0126 (MEK1/2 inhibitor), SB203580
(p38 inhibitor), and SP600125 (JNK inhibitor)), PI3K in-
hibitor wortmannin, FGFR antagonist (PD173074 (pan-
FGFR blocker), SU11652 (selective FGFR1 blocker)), and
IWR-1-endo (Wnt antagonist) were purchased from Cal-
biochem (Gibbstown, NJ, USA). FGF-2 neutralizing anti-
body (aFGF-2) was purchased from Millipore (Billerica,
MA, USA), and FKN neutralizing antibody (aFKN) was
purchased as previously described [25].
Preparation of Aβ solutions
Aβ1-42 solution was prepared as previously described
[26]. Briefly, synthetic human Aβ1-42 (Peptide Institute,
Osaka, Japan) was dissolved to 1 mM in 100% 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP). The HFIP was dried and
resuspended to a concentration of 5 mM in DMSO. To
form oligomers, amyloid peptide was diluted to a final
concentration of 100 μM with Ham’s F-12, incubated at 4°C
for 24 h, and then immediately added to cultures at a final
concentration of 5 μM.
Cell culture
The protocols for animal experiments were approved by
the Animal Experiment Committee of Nagoya University.
Primary neuronal cultures were prepared from the corti-
ces of C57BL/6 mice embryos at embryonic day 17 (E17)
as described previously [27]. Briefly, cortical fragments
were dissociated into single cells in dissociation solution
(Sumitomo Bakelite, Akita, Japan), and resuspended in nerve
culture medium (Sumitomo Bakelite). Neurons were
seeded onto 12 mm polyethylenimine-coated glass cov-
erslips (Asahi Techno Glass Corp., Chiba, Japan). The
purity of the cultures was greater than 95%, as deter-
mined by NeuN-specific immunostaining [28].
Microglia were isolated from primary mixed glial cell
cultures prepared from newborn C57BL/6 mice at day
in vitro (DIV) 14 using the ‘shaking off ’ method, which
has been described previously [29]. The purity of the cul-
tures was 97 to 100% as determined by immunostaining
for the Fc receptor. Cultures were maintained in DMEM
supplemented with 10% fetal calf serum, 5 μg/ml bovine
insulin, and 0.2% glucose. Astrocytes were purified from
primary mixed glial cultures by three or four repetitions of
trypsinization and replating. The purity of astrocytes was
greater than 95%, as determined by GFAP-specific immu-
nostaining [30].
Measurement of FGF-2 levels
Secreted FGF-2 from mouse primary astrocytes, cortical
neurons, and microglia were measured using an ELISA
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treated with L-glutamate (20 μM) or oAβ (5 μM) for 6
to 24 h at 37°C. Supernatants were then collected and
assessed for FGF-2 levels.
Western blotting
Microglial cell lysates were boiled after the addition of
sample buffer (1 M Tris-HCl, 20% sodium dodecyl sulfate
(SDS), and 2.5% glycerol). Fifty micrograms of total pro-
tein were separated on a 5 to 20% Tris-glycine SDS-
polyacrylamide gel and blotted onto Hybond-P polyvinyli-
dene difluoride (PVDF) membranes (GE Healthcare UK,
Buckinghamshire, UK). Membranes were blocked with 1%
skim milk in Tris-buffered saline containing 0.05% Tween
20 for 1 h at room temperature. Primary antibodies to
detect phosphorylated and total MAPK (Cell Signaling,
Danvers, MA, USA) were applied at the concentrations
recommended by the manufacturers. The secondary anti-
body was horseradish peroxidase-conjugated anti-rabbit
IgG (GE Healthcare), which was used at a dilution of
1:1000. SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Fisher Scientific, Rockford, IL, USA)
was used according to the manufacturer’s instructions.
The intensities of the bands were calculated using the
CS Analyzer 1.0 (Atto Corporation, Tokyo, Japan).
Wnt promoter assay
HEK293T cells were seeded one day before transfection
by FuGENE HD (Promega, Madison, WI, USA) with a
luciferase reporter vector from the Cignal TCF/LEF Re-
porter (luc) kit (Wnt promoter assay system), which was
purchased from SABiosciences (Qiagen KK, Tokyo, Japan).
After drug treatment, cells were lysed and luciferase re-
porter activity was measured using the Dual luciferase re-
porter assay kit (Promega) and a Wallac 1420 ARVOMX
(PerkinElmer Japan, Yokohama, Japan).
Evaluation of microglial phagocytosis
A microglial phagocytosis assay was performed as previ-
ously described [25]. Briefly, primary mouse cortical
neurons in 24-well plates were labeled on DIV 14 with
1 μM CM-DiI (Molecular Probes), and treated with
20 μM glutamate overnight at 37°C. After changing the
culture medium, microglia were added to these neuronal
cultures (1:2 ratio for neurons to microglia) with or
without FGF-2 for 24 h. Cells were subsequently fixed in
4% paraformaldehyde. Microglia were stained with Cy5-
conjugated rat anti-mouse CD11b monoclonal antibodies
prior to fixation. Phagocytic uptake of neuronal debris by
microglia was estimated based on the detection of DiI-
stained neuronal debris [31] in CD11b-positive microglia
(green); the phagocytosis index was calculated as the per-
centage of red staining that overlapped with green staining
(shown in yellow) among all of the microglia.Immunocytochemistry
Cells were fixed with 4% paraformaldehyde, blocked, and
permeabilized. Neurons were stained with mouse poly-
clonal anti–MAP-2 antibody (1:1000; Chemicon, Temecula,
CA, USA) and secondary antibody conjugated to Alexa 488
(1:1000; Invitrogen). Astrocytes were stained with mouse
monoclonal anti-GFAP antibody (Sigma) and secondary
antibody conjugated to Alexa 647 (1:1000; Invitrogen).
Microglia were stained with Cy5-conjugated rat anti-mouse
CD11b monoclonal antibody (1:300, BD Pharmingen) prior
to fixation. Images were analyzed using a deconvolution
fluorescence microscope system (BZ-8000; Keyence
Corporation, Osaka, Japan). The other primary anti-
bodies included FGFRs, which were purchased from R
& D systems and used according to the manufacturer’s
instructions.
Surviving neurons were identified based on their cyto-
skeletons as previously described [28]. Viable neurons
were strongly stained with anti-MAP-2 antibodies, whereas
damaged neurons showed weaker staining. MAP-2-positive
neurons were counted in representative areas in each well.
Using five independent trials, more than 200 neurons
were evaluated in each well by a scorer who was blind to
the experimental conditions. The number of viable neu-
rons in untreated cultures was set as 100%.
Measurement of CCL3 (MIP-1a), NO, and glutamate levels
Supernatants from microglia were assessed using the
chemokine (C-C motif ) ligand 3 (CCL3) ELISA kit (R &
D Systems), and a Griess reaction for nitric oxide (NO)
detection. To measure glutamate levels, a colorimetric assay
kit (Yamasa Corporation, Tokyo, Japan) was used, as pre-
viously described [25].
MTS assay
To evaluate the viability of the cells, we used the CellTiter
96 Aqueous One Solution Cell Proliferation Assay kit
(Promega) and followed the manufacturer’s instructions.
Microglial migration assay
Microglial migration was performed using Transwell
plates with 3 μm pore polyethylene terephthalate (PET)
membrane filters (BD Biosciences). We placed 800 μl
of neuronal-conditioned medium or microglial culture
medium treated with drugs into the lower chamber of
the Transwell plate. Membrane filters were then put in
vacant wells, and 200 μl of microglia-containing medium
(1.0 × 105 cells/well) was carefully added on top of the fil-
ter membrane to avoid bubbles. These plates were incu-
bated for 24 h. Cells that migrated into the lower wells
were counted by fluorescence-activated cell sorting
(FACS). Chemokine-treated T cells (combination of FKN
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for this method, as previously described [32].
RT-PCR
Total RNA was extracted from astrocytes, microglia, and
neurons using an RNeasy Mini Kit (Qiagen, Tokyo,
Japan). A first-strand cDNA library was obtained using
SuperScript II (Invitrogen, Carlsbad, CA) and oligo (dT)
12-18 (Invitrogen) as the first-strand primer. Negative
control reactions were performed using the same system
after heat denaturation of reverse transcriptase. RT-PCR
was used to amplify transcripts encoding mouse FGF-2,
each receptor subtypes and glyceraldehydes-3-phosphate
dehydrogenase (GAPDH), using 0.1 μg of first-strand
cDNA, Blend Taq polymerase (Toyobo Co., Osaka, Japan),
and oligonucleotide primers (Table 1; except for previ-
ously described primers for GAPDH [25]).
Statistical analysis
Statistically significant differences between experimental
groups were determined by one-way analysis of variance
(ANOVA) followed by Dunnett’s or Tukey’s tests for mul-
tiple comparisons. Statistical analysis was performed using
the software program Prism 4 for Windows (GraphPad
Software, San Diego, CA, USA). P values less than 0.05
were considered significant.
Results
Expression of FGFRs in primary neurons and glial cells
We first examined the expression of FGFRs in the CNS.
According to our immunocytochemical (Figure 1A) and
RT-PCR (Figure 1B) data, all FGF receptors (FGFR1 to 5)
were expressed in astrocytes. FGFR1 to 4 were expressed
in neurons and microglia. The expression of FGF-2 mRNA
was detected in neurons and astrocytes.Table 1 Oligonucleotide primers used in RT-PCR

























5′-GGATTACATCCACTTTGTAGGTGlutamate or oAβ enhances FGF-2 release from neurons,
and FGF-2 induces microglial neuroprotection via FGFR3
FGF-2 is widely expressed in the CNS, especially in as-
trocytes, while FGF-5, FGF-8, and FGF-9 are synthesized
by neurons [33]. FGF-2 is reported to be produced by
cerebellar granule neurons in co-cultures with microglia,
and to abrogate quinolinic acid–mediated neurotoxicity
[31]. In this study, we investigated whether cortical neu-
rons could produce FGF-2 in response to neurotoxic
stimuli. We found that treatment for 6 h and 24 h with
20 μM glutamate or 5 μM oAβ significantly induced
FGF-2 release from cortical neurons (Figure 2A). Astro-
cytes typically secrete FGF-2; however, various stimuli
including glutamate, oAβ, lipopolysaccharide (LPS), and
other proinflammatory cytokines did not enhance FGF-2
secretion by astrocytes (Figure 2B). Furthermore, FGF-2
secretion by microglia was barely detectable (Figure 2B).
Next, we determined whether FGF-2 might exert micro-
glial neuroprotection. As shown in Figure 3A,B, treatment
with 20 μM glutamate induced apparent neuronal cell
death in neuron-microglia co-cultures. The addition of
100 ng/ml FGF-2 significantly ameliorated neurotoxicity,
while an anti-FGF-2 antibody canceled the effect. The
addition of rat IgG (isotype-matched control for anti-
FGF-2 antibody) had no effect on cell survival rate. In
neuronal cultures, neuronal cell death was not ameliorated
by FGF-2 treatment. There seems to be little difference
in neuronal survival against Glu-induced excitotoxicity
with or without microglia. We considered that the se-
creted level of FGF-2 from Glu-treated neurons might
not reach the effective dose to enhance the neuronal
survival. In addition, FGF-2 treatment suppressed the pro-
inflammatory response of activated microglia through the
inhibition of neurotoxic molecules, such as glutamate and
NO (Additional file 1: Figure S1A,B). FGF-2 had no effect
on microglial proliferation (Additional file 1: Figure S1C).
FGF-2 dose-dependently enhanced the neuronal survival
in the presence of microglia (Additional file 1: Figure S2).
To investigate the underlying mechanism of neuropro-
tection by FGF-2 in microglia, we used FGFR inhibitors
and neutralizing antibodies. The neuroprotective effect of
100 ng/ml FGF-2 was completely canceled by treatment
with pan-FGFR inhibitor PD173074, or anti-FGFR3 neu-
tralizing antibody. Conversely, neutralizing antibodies for
FGFR1, 2, 4, and 5, selective FGFR1 blocker SU11652, and
isotype control of neutralizing antibodies had no effect on
neuronal survival (Figure 3C,D).
CCL3 (MIP-1α) is reported to be a downstream target
of FGF-2-induced FGFR3 signaling [34]. FGF-1-induced
FGFR3 targets include the Na+ channel, type III inter-
mediate filament peripherin, and cell surface glycoprotein
Thy1 [34,35]. We confirmed that FGF-2 leads to the in-
duction of CCL3 expression in microglia. Using ELISA,























Figure 1 Expression of FGF-2 and FGFRs in primary neurons and glial cells. (A) Expression of FGFRs as assessed by immunocytochemistry:
FGFRs (green), MAP-2 (mature cortical neurons; red), CD11b (microglia; red), and GFAP (astrocytes; red). Scale bars, 10 μm in neurons and microglia,
and 50 μm in astrocytes. (B) Expression of FGF-2 and FGFR1 to FGFR5 mRNA in mature cortical neurons (Neu), microglia (Mi) and astrocytes (Ast), as
assessed by RT-PCR. GAPDH expression is used as a control.
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CCL3 is known as a proinflammatory chemokine, FGF-2
did not activate microglia in this study.
FGF-2-induced microglial neuroprotection via ERK MAPK
and ERK activation is directly regulated by Wnt signaling
To elucidate the signaling pathway of microglia-mediated
neuroprotection, we examined the effect of several kinase
inhibitors on neuronal survival. MAPKs (ERK, p38, and
JNK) and phosphoinositide-3 kinase (PI3K) are known as
common downstream signaling pathways of FGFRs. We
found that inhibition of ERK by U0126 significantly sup-
pressed FGF-2-induced microglial neuroprotection. Other
kinase inhibitors (p38, JNK, MAPK, and PI3K inhibitors)
did not affect neuroprotection (Figure 4A,B). U0126 might
affect both microglia and neurons in the co-culture model.The effects of this signaling on neurons cannot be denied.
As shown in Figure 4C, FGF-2 increased ERK phosphoryl-
ation in microglia, which peaked within 15 min.
In developmental morphogenic stages and angiogenesis,
the coordinated action of Wnt/β-catenin and FGF signal-
ing has been reported [23,24,36]. It has also been reported
that mouse primary microglia express the Wnt receptors
Frizzled and LDL-related protein 5/6 [37]. Therefore, to
clarify the interaction of Wnt signaling with FGF in
microglia, we examined the effect of Wnt inhibitor on
ERK phosphorylation by FGF-2. Pre-treatment of Wnt an-
tagonist IWR-1-endo showed remarkable inhibition of
ERK activation (Figure 4D). FGF-2 also directly increased
TCF/LEF promoter activity, which is the downstream tar-
get of the Wnt signaling pathway. The FGF-2-induced
TCF/LEF promoter activity was completely abrogated by











Figure 2 The detection of FGF-2 in primary neurons and glial cells.
(A) Neurons were treated with glutamate (Glu) or oligomeric amyloid
β1-42 (oAβ) at the indicated concentrations. FGF-2 concentrations in
the neuronal culture supernatants were measured using ELISAs at each
time point. Results show the means with SEM (n = 3). Significant
differences compared with untreated samples. *: P < 0.05, **: P < 0.01
(one-way ANOVA with Dunnett’s post-hoc test). (B) Astrocytes, microglia
and neurons were treated with Glu (20 μM) or oAβ (5 μM) for 6 h. Other
treatments of astrocytes (6 h) were LPS (1 μg/ml), TNF-α (20 ng/ml),
IFN-γ (10 ng/ml), and a combination of all three. ELISA was then
performed to detect FGF-2 concentration in the culture supernatants.
The results show the means with SEM (n = 3). Significant
differences compared with untreated samples in each cell type.
*: P < 0.05, ***: P < 0.001, n.s.: not significant (one-way ANOVA
with Dunnett’s post-hoc test).
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neuronal debris via FGFR3 and Wnt pathway signaling
We next examined the effect of FGF-2 on microglial mi-
gration and phagocytosis activity. We established a micro-
glial migration assay, and assessed migration via the
Transwell cell culture system. Microglial migration was
significantly increased by CCL21, CCL21 plus FKN, and
FGF-2 (Additional file 1: Figure S4). We also confirmed
the availability of this system in our previous report [32].
T cells from mouse lymph node showed drastic migration
by CCL21 plus FKN (Additional file 1: Figure S4B).
Neuronal-conditioned media treated with 20 μM glutamate
for 24 h can significantly attract microglia (Additional file 1:
Figure S4C). As shown in Figure 5A, while fresh neur-
onal media did not induce microglial migration, un-
treated neuronal-conditioned media significantly enhancedmigration. Furthermore, it has been determined that
neuronal-conditional media treated with 20 μM glutamate
for 24 h is a more potent attractant to microglia. This ef-
fect was canceled by aFGF-2, but not aFKN (Figure 5A).
We also revealed that addition of 100 ng/ml FGF-2 to the
lower part of the Transwell system significantly enhanced
microglial migration (Figure 5B). The effect was canceled
by pan-FGFR inhibitor PD173074 and aFGFR3 neutraliz-
ing antibody.
Wnt signaling maintains cell migration in the develop-
mental stages. Therefore we next examined whether Wnt
signaling could also mediate microglial migration. Wnt
antagonist IWR-1-endo dose-dependently attenuated the
induction of microglial migration by FGF-2 (Figure 5C).
By contrast, ERK MAPK pathway was not directly con-
cerned with microglial migration (Additional file 1:
Figure S4D). Furthermore, FGF-2 enhanced microglial
phagocytosis of neuronal debris induced by glutamate
toxicity (Figure 5D,E). We examined which type of FGFR
is involved in the FGF-2-induced phagocytosis, and found
that pan-FGFR inhibitor PD173074 and anti-FGFR3 neu-
tralizing antibody suppressed microglial phagocytosis of
neuronal debris (Figure 5D,E).
Discussion
Our results indicate that FGF-2 is released from degenerat-
ing neurons and induces microglial migration and neuropro-
tection, which are mediated through the FGFR3-Wnt-ERK
signaling pathway. Neurons were fine responders of glutam-
ate and oAβ, and then allowed the release of FGF-2 in rela-
tively short times. FGF receptors are expressed in neurons
and glial cells. FGFR3, in particular, is activated by FGF-2
via the ERK MAPK-dependent signaling pathway in
microglia. The other FGF, FGF-19, is reported to nega-
tively regulate NFκB via FGFR4 [38]. In the developmental
morphogenic stages and angiogenesis, coordinated action
of Wnt/β-catenin and FGF signaling has been reported
[12,23,24,39]. Recently, expression of Wnt receptors
Frizzled and LDL receptor-related protein 5/6 has been
reported in mouse primary microglia [37]. In this study,
we revealed that FGF-2 directly controlled the Wnt sig-
naling pathway in mouse primary microglia, and that
Wnt signaling could also directly regulate microglial mi-
gration induced by FGF-2. FGF-2 and the extracellular
matrix protein Anosmin-1 have dynamic roles in cellular
proliferation and migration from the subventricular zone
in CNS development [40]. FGF-2 enhances the prolifera-
tion and differentiation of neuronal stem cells. Anosmin-1
and FGF-2 could possibly be diagnostic markers in mul-
tiple sclerosis (MS), because their expression level varies
between different types of MS [16]. In experimental auto-
immune encephalomyelitis, the animal model of MS,
FGF-2 may act as a remyelinating and nerve fiber pre-














Figure 3 The neuroprotective effects of FGF-2 in neuron-microglia co-cultures. (A) Neuronal cultures were also treated with Glu and FGF-2.
Neurons were stained with anti-MAP-2 antibody (green), and microglia were stained with a Cy5-conjugated anti-CD11b antibody (red). Scale bars,
50 μm. (B) The neuronal survival rate was calculated as the percentage of intact neurons in the treated sample relative to the untreated sample.
The columns indicate mean with SEM from three independent experiments. * indicates significant differences compared with untreated neuronal
cultures (***: P < 0.001); + indicates significant differences compared with untreated neuron–microglia co-cultures (+++: P < 0.001) by one-way
ANOVA with Tukey’s post-hoc test. (C) After treatment with 20 μM Glu and 100 ng/ml FGF-2, the inhibitory effects of FGFR were evaluated using
FGFR blockers or each anti-FGFR neutralizing antibody (PD, pan-FGFR blocker, 1 μM PD173074; SU, selective FGFR1 blocker, 500 nM SU11652; aR2,
anti-FGFR2 antibody; aR3, anti-FGFR3 antibody; aR4, anti-FGFR4 antibody; aR5, anti-FGFR5 antibody; or isotype-matched IgG control). (D) The neur-
onal survival rate was calculated. The columns indicate the means with SEM from three independent experiments, each of which included the
analysis of ten randomly selected fields. Significant differences compared with FGF-2-treatment were noted. **: P < 0.01, ***: P < 0.001 (one-way
ANOVA with Tukey’s post-hoc test).
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to maintain adult CNS function.
Localized delivery of FGF-2 and brain-derived neuro-
trophic factor (BDNF) to the lesioned hippocampus in-
creases neurogenesis and reduces epileptogenesis in a ratmodel of epilepsy [42]. The overexpression of FGF-2/
BDNF also attenuates neuroinflammation through sup-
pression of IL-1β [43]. Moreover, FGF-2 gene delivery
restores hippocampal functions in an Alzheimer’s dis-
ease mouse model [44]. FGF-2 has a deep connection
ERK
p-ERK





















Figure 4 FGF-2 exhibits neuroprotection via ERK MAPK signaling pathway. (A) Effects of MAPK and PI3K inhibitors on neuroprotection of
FGF-2. U0126, MEK1/2 inhibitor U0126 (1 μM); SP, JNK inhibitor SP600125 (10 μM); SB, p38 inhibitor SB203580 (10 μM); WM, PI3K inhibitor wortmannin
(2 μM). (B) Neuronal survival rate. Columns indicate mean with SEM from three independent experiments. ***: P < 0.001 compared with the cultures
without inhibitors (one-way ANOVA with Dunnett’s post-hoc test). (C) Protein extracts from primary microglia were analyzed by immunoblotting with
antibodies specific for phosphorylated and total ERK (ERK1/2). Cells were treated with 100 ng/ml FGF-2 for the indicated periods. *: P < 0.05 compared
with untreated control (0 min) samples (one-way ANOVA with Dunnett’s post-hoc test). (D) Microglia were treated with U0126 (1 μM) or Wnt antagonist
IWR-1-endo (300 nM) overnight and then 100 ng/ml FGF-2 for 15 min. Western blotting of phosphorylated and total ERK was performed. * indicates
significant differences compared with untreated samples (*: P < 0.05, ***: P < 0.001); + indicates significant differences compared with FGF-2 treatment
alone (+++: P < 0.001) by one-way ANOVA with Tukey’s post-hoc test. (E) Wnt promoter assay. HEK293T cells were transfected with Wnt promoter
bearing the firefly luciferase reporter vector and Renilla luciferase reporter vector as a transfection control. After 24 h incubation, cells were treated with
IWR-1-endo and U0126 overnight, and then treated with FGF-2 for 4 h. Cells were lysed and measured for luciferase activity. **: P < 0.01 compared with
FGF-2 treatment alone (one-way ANOVA with Dunnett’s post-hoc test).
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man inflammatory macrophages into the extravascular
compartment depends on binding of FGF-2 to the
CD44 receptor [45]. Therefore, it is possible that FGF-2has functional association with a new counterpart other
than FGFRs.
The brain concentration of FGF2 is reported to be











Figure 5 Effects of FGF-2 on cellular migration and clearance of degenerated neuronal debris by microglia. (A) Microglial migration
assay; aFKN or aFGF-2 were added to lower plates and microglia set on upper Transwell inserts and cultured for 48 h, with isotype-matched
IgG as control. Migrated cells in lower plates were counted by FACS. One-way ANOVA with Tukey’s post-hoc test: *, significant difference
compared with untreated samples using healthy conditioned medium (***: P < 0.001); +, significant difference compared with untreated samples
(n.s., not significant; +, P < 0.05). (B) Effect of FGFR blockers and antibodies on microglial migration induced by 100 ng/ml FGF-2. PD, pan-FGFR blocker
1 μM PD173074; SU, selective FGFR1 blocker 500 nM SU11652; aR2, anti-FGFR2 antibody; aR3, anti-FGFR3 antibody; aR4, anti-FGFR4 antibody;
aR5, anti-FGFR5 antibody; isotype-matched IgG control. **, P < 0.01 compared with FGF-2 treatment alone (one-way ANOVA with Dunnett’s
post-hoc test). (C) Effect of IWR-1-endo on microglial migration induced by FGF-2 treatment. **, P < 0.01 compared with FGF-2 treatment alone
(one-way ANOVA with Dunnett’s post-hoc test). (D) Microglial phagocytosis assay. CM-DiI-labeled neurons were treated with or without
glutamate, and microglia were added to the culture. These cells were treated with or without 100 ng/ml FGF-2 and with FGFR blockers or each
of the anti-FGFR neutralizing antibodies of (B) for 24 h. Scale bars, 20 μm. (E) Phagocytosis index, defined as the percentage of total microglia
staining (green) overlapping with DiI staining (red). Columns indicate mean with SEM from three independent experiments. Significant
differences compared with sample used degenerated neuronal debris and FGF-2 treatment: **, P < 0.01; ***, P < 0.001 (one-way ANOVA
with Tukey’s post-hoc test).
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In a future study, we will attempt to clarify the effect of
100 ng/ml FGF2 in vivo. Taken together, the present
study shows that FGF-2 from damaged neurons functions
as help-me and eat-me signals. Targeting the FGF-2/
FGFR3 pathway may give us clues for future therapeutic
strategy against neurodegenerative diseases.
Conclusions
The present study shows that FGF-2 could be a key signal-
ing molecule for crosstalk between degenerating neurons
and microglia, and the FGFR3/ERK/Wnt signaling path-
way in microglia contributes to the induction of neuropro-
tective function including migration and phagocytosis of
neuronal debris. Therefore, FGF-2 from damaged neurons
functions as help-me and eat-me signals to microglia.
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Abbreviations
aFGF2: anti-FGF2 neutralizing antibody; aFKN: anti-FKN neutralizing antibody;
ANOVA: analysis of variance; BDNF: brain-derived neurotrophic factor;
CNS: central nervous system; DIV: day in vitro; DMEM: Dulbecco’s modified
Eagle medium; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent
assay; ERK: extracellular signal-regulated kinase; FACS: fluorescence-activated cell
sorting; FKN: fractalkine; FGF: fibroblast growth factor; FGFR: fibroblast
growth factor receptor; GAPDH: glyceraldehydes-3-phosphate dehydrogenase;
HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol; IgG: immunoglobulin G; LPS: lipopolysaccharide;
MS: multiple sclerosis; oAβ: oligomeric amyloid β; PD: pan-FGFR blocker;
PET: polyethylene terephthalate; PVDF: polyvinylidene difluoride; RT-PCR: reverse
transcriptase polymerase chain reaction; SDS: sodium dodecyl sulfate;
SEM: standard error of the mean.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MN conducted the ELISAs, microglial phagocytosis assay, FACS analysis, and
statistical analysis, and drafted the manuscript. KT performed the RT-PCR
experiments and helped draft the manuscript. BP and JK performed the
cell culture and were involved in the conception of the study. YS and HT
were also involved in the conception of the study. TM carried out the
immunocytochemistry and statistical analysis. He was also involved in the
conception and design of the study, and helped draft the manuscript. AS was
also involved in the conception and design of the study, as well as in preparing
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by JSPS KAKENHI Grant Number 24659430, a grant
from the Advanced Research for Medical Products Mining Programme of the
National Institute of Biomedical Innovation (NIBIO), and grants from the
Ministry of Health, Labour and Welfare of Japan.
Author details
1Department of Neuroimmunology, Research Institute of Environmental
Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.
2Present address: Department of Anatomy, Keio University School of
Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.Received: 23 January 2014 Accepted: 26 March 2014
Published: 16 April 2014References
1. Mehta SL, Manhas N, Raghubir R: Molecular targets in cerebral ischemia
for developing novel therapeutics. Brain Res Rev 2007, 54:34–66.
2. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH: Mechanisms
underlying inflammation in neurodegeneration. Cell 2010, 140:918–934.
3. Gold SM, Mohr DC, Huitinga I, Flachenecker P, Sternberg EM, Heesen C: The
role of stress-response systems for the pathogenesis and progression of
MS. Trends Immunol 2005, 26:644–652.
4. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER,
Armstrong AJ, Penuela S, Laird DW, Salvesen GS, Isakson BE, Bayliss DA,
Ravichandran KS: Pannexin 1 channels mediate ‘find-me’ signal release
and membrane permeability during apoptosis. Nature 2010, 467:863–867.
5. Grimsley C, Ravichandran KS: Cues for apoptotic cell engulfment: eat-me,
don’t eat-me and come-get-me signals. Trends Cell Biol 2003, 13:648–656.
6. Lu Z, Elliott MR, Chen Y, Walsh JT, Klibanov AL, Ravichandran KS, Kipnis J:
Phagocytic activity of neuronal progenitors regulates adult
neurogenesis. Nat Cell Biol 2011, 13:1076–1083.
7. Ravichandran KS: Find-me and eat-me signals in apoptotic cell clearance:
progress and conundrums. J Exp Med 2010, 207:1807–1817.
8. Napoli I, Neumann H: Microglial clearance function in health and disease.
Neuroscience 2009, 158:1030–1038.
9. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A: Physiology of microglia.
Physiol Rev 2011, 91:461–553.
10. Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector
cells in the normal and pathologic brain. Nat Neurosci 2007,
10:1387–1394.
11. Noda M, Suzumura A: Sweepers in the CNS: microglial migration and
phagocytosis in the Alzheimer disease pathogenesis. Int J Alzheimers Dis
2012, 2012:891087.
12. Aman A, Piotrowski T: Wnt/β-catenin and Fgf signaling control collective
cell migration by restricting chemokine receptor expression. Dev Cell
2008, 15:749–761.
13. Aman A, Piotrowski T: Cell-cell signaling interactions coordinate multiple
cell behaviors that drive morphogenesis of the lateral line. Cell Adh Migr
2011, 5:499–508.
14. Ma EY, Raible DW: Signaling pathways regulating zebrafish lateral line
development. Curr Biol 2009, 19:R381–R386.
15. Hossain WA, Morest DK: Fibroblast growth factors (FGF-1, FGF-2) promote
migration and neurite growth of mouse cochlear ganglion cells in vitro:
immunohistochemistry and antibody perturbation. J Neurosci Res 2000,
62:40–55.
16. Clemente D, Ortega MC, Arenzana FJ, de Castro F: FGF-2 and Anosmin-1
are selectively expressed in different types of multiple sclerosis lesions.
J Neurosci 2011, 31:14899–14909.
17. Gehrmann J, Lannes-Vieira J, Wekerle H: Differential expression of fibroblast
growth factor-2 and receptor by glial cells in experimental autoimmune
encephalomyelitis (EAE). Glia 1996, 16:93–100.
18. Riva MA, Molteni R, Lovati E, Fumagalli F, Rusnati M, Racagni G: Cyclic
AMP-dependent regulation of fibroblast growth factor-2 messenger RNA
levels in rat cortical astrocytes: comparison with fibroblast growth
factor-1 and ciliary neurotrophic factor. Mol Pharmacol 1996, 49:699–706.
19. Ganat Y, Soni S, Chacon M, Schwartz ML, Vaccarino FM: Chronic hypoxia
up-regulates fibroblast growth factor ligands in the perinatal brain and
induces fibroblast growth factor-responsive radial glial cells in the
sub-ependymal zone. Neuroscience 2002, 112:977–991.
20. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K,
Watson JD, Murison JG: Identification of a new fibroblast growth factor
receptor, FGFR5. Gene 2001, 271:171–182.
21. Logan A, Frautschy SA, Gonzalez AM, Baird A: A time course for the focal
elevation of synthesis of basic fibroblast growth factor and one of its
high-affinity receptors (flg) following a localized cortical brain injury.
J Neurosci 1992, 12:3828–3837.
22. Goddard DR, Berry M, Kirvell SL, Butt AM: Fibroblast growth factor-2 induces
astroglial and microglial reactivity in vivo. J Anat 2002, 200:57–67.
23. Aman A, Nguyen M, Piotrowski T: Wnt/β-catenin dependent cell
proliferation underlies segmented lateral line morphogenesis. Dev Biol
2011, 349:470–482.
Noda et al. Journal of Neuroinflammation 2014, 11:76 Page 11 of 11
http://www.jneuroinflammation.com/content/11/1/7624. Holnthoner W, Pillinger M, Groger M, Wolff K, Ashton AW, Albanese C,
Neumeister P, Pestell RG, Petzelbauer P: Fibroblast growth factor-2 induces
Lef/Tcf-dependent transcription in human endothelial cells. J Biol Chem
2002, 277:45847–45853.
25. Noda M, Doi Y, Liang J, Kawanokuchi J, Sonobe Y, Takeuchi H, Mizuno T,
Suzumura A: Fractalkine attenuates excito-neurotoxicity via microglial
clearance of damaged neurons and antioxidant enzyme heme
oxygenase-1 expression. J Biol Chem 2011, 286:2308–2319.
26. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M, Michikawa M,
Takeuchi H, Suzumura A: Microglia activated with the toll-like receptor 9
ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and
in vivo models of Alzheimer’s disease. Am J Pathol 2009, 175:2121–2132.
27. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N,
Suzumura A: Neuroprotective role of phosphodiesterase inhibitor
ibudilast on neuronal cell death induced by activated microglia.
Neuropharmacology 2004, 46:404–411.
28. Banno M, Mizuno T, Kato H, Zhang G, Kawanokuchi J, Wang J, Kuno R, Jin S,
Takeuchi H, Suzumura A: The radical scavenger edaravone prevents
oxidative neurotoxicity induced by peroxynitrite and activated microglia.
Neuropharmacology 2005, 48:283–290.
29. Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH: MHC antigen
expression on bulk isolated macrophage-microglia from newborn mouse
brain: induction of Ia antigen expression by γ-interferon. J Neuroimmunol
1987, 15:263–278.
30. Mizuno T, Kawanokuchi J, Numata K, Suzumura A: Production and
neuroprotective functions of fractalkine in the central nervous system.
Brain Res 2003, 979:65–70.
31. Figueiredo C, Pais TF, Gomes JR, Chatterjee S: Neuron-microglia crosstalk
up-regulates neuronal FGF-2 expression which mediates neuroprotection
against excitotoxicity via JNK1/2. J Neurochem 2008, 107:73–85.
32. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y,
Mizuno T, Suzumura A: IL-9 promotes Th17 cell migration into the central
nervous system via CC chemokine ligand-20 produced by astrocytes.
J Immunol 2011, 186:4415–4421.
33. Reuss B, von Bohlen und, Halbach O: Fibroblast growth factors and their
receptors in the central nervous system. Cell Tissue Res 2003, 313:139–157.
34. Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E,
Roodman D, Claudio JO, Bergsagel PL, Stewart AK: MIP-1α (CCL3) is a
downstream target of FGFR3 and RAS-MAPK signaling in multiple
myeloma. Blood 2006, 108:3465–3471.
35. Choi DY, Toledo-Aral JJ, Lin HY, Ischenko I, Medina L, Safo P, Mandel G,
Levinson SR, Halegoua S, Hayman MJ: Fibroblast growth factor receptor 3
induces gene expression primarily through Ras-independent signal
transduction pathways. J Biol Chem 2001, 276:5116–5122.
36. Katoh M, Katoh M: Cross-talk of WNT and FGF signaling pathways at
GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol
Ther 2006, 5:1059–1064.
37. Halleskog C, Mulder J, Dahlstrom J, Mackie K, Hortobagyi T, Tanila H, Kumar Puli L,
Farber K, Harkany T, Schulte G: WNT signaling in activated microglia is
proinflammatory. Glia 2011, 59:119–131.
38. Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ: The receptor
tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.
PLoS One 2010, 5:e14412.
39. Sasaki T, Ito Y, Xu X, Han J, Bringas P Jr, Maeda T, Slavkin HC, Grosschedl R,
Chai Y: LEF1 is a critical epithelial survival factor during tooth
morphogenesis. Dev Biol 2005, 278:130–143.
40. Garcia-Gonzalez D, Clemente D, Coelho M, Esteban PF, Soussi-Yanicostas N,
de Castro F: Dynamic roles of FGF-2 and Anosmin-1 in the migration of
neuronal precursors from the subventricular zone during pre- and
postnatal development. Exp Neurol 2010, 222:285–295.
41. Rottlaender A, Villwock H, Addicks K, Kuerten S: Neuroprotective role of
fibroblast growth factor-2 in experimental autoimmune encephalomyelitis.
Immunology 2011, 133:370–378.
42. Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A,
Mazzuferi M, Magri E, Navarro Mora G, Rodi D, Su T, Volpi I, Zanetti L,
Marzola A, Manservigi R, Fabene PF, Simonato M: Localized delivery of
fibroblast growth factor-2 and brain-derived neurotrophic factor reduces
spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 2009,
106:7191–7196.43. Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Navarro Mora G,
Osculati F, Berto E, Marconi P, Marzola A, Fabene PF, Simonato M:
Hippocampal FGF-2 and BDNF overexpression attenuates
epileptogenesis-associated neuroinflammation and reduces spontaneous
recurrent seizures. J Neuroinflammation 2010, 7:81.
44. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: FGF2 gene transfer
restores hippocampal functions in mouse models of Alzheimer’s disease
and has therapeutic implications for neurocognitive disorders. Proc Natl
Acad Sci USA 2011, 108:E1339–E1348.
45. Jones M, Tussey L, Athanasou N, Jackson DG: Heparan sulfate
proteoglycan isoforms of the CD44 hyaluronan receptor induced in
human inflammatory macrophages can function as paracrine regulators
of fibroblast growth factor action. J Biol Chem 2000, 275:7964–7974.
46. Kim J, Gale K, Kondratyev A: Effects of repeated minimal electroshock
seizures on NGF, BDNF and FGF-2 protein in the rat brain during postnatal
development. Int J Dev Neurosci 2010, 28:227–232.
47. Mellergard P, Sjogren F, Hillman J: Release of VEGF and FGF in the
extracellular space following severe subarachnoidal haemorrhage or
traumatic head injury in humans. Br J Neurosurg 2010, 24:261–267.
48. Mellergard P, Sjogren F, Hillman J: The cerebral extracellular release of
glycerol, glutamate, and FGF2 is increased in older patients following
severe traumatic brain injury. J Neurotrauma 2012, 29:112–118.
doi:10.1186/1742-2094-11-76
Cite this article as: Noda et al.: FGF-2 released from degenerating
neurons exerts microglial-induced neuroprotection via FGFR3-ERK
signaling pathway. Journal of Neuroinflammation 2014 11:76.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
